 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
7 News |  |
- Easyef (nepidermin) / Daewoong Pharma
Cost-Effectiveness Analysis of the Use of Negative Pressure Wound Therapy in the Treatment of Diabetic Foot Disease in Colombia () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1757;
NPWT seems to offer a better cost-effectiveness ratio with respect to hEGF, but not to TOT in Colombia. The main limitation of this study centers on the absence of non-inferiority clinical trials with a long-term horizon.
- | Easyef (nepidermin) / Daewoong Pharma
Journal: Efficacy Comparison Study of Human Epidermal Growth Factor (EGF) between Heberprot-P and Easyef in Adult Zebrafish and Embryo under Presence or Absence Combination of Diabetic Condition and Hyperlipidemia to Mimic Elderly Patients. (Pubmed Central) - Apr 22, 2022
Treatment of Heberprot-P75 induced a greater developmental speed of zebrafish embryos in both water exposure and microinjection. Heberprot-P75 induced significantly higher wound healing and tissue regeneration activity than Easyef and PBS in the presence or absence of diabetic conditions and cholesterol supplementation.
- | Easyef (nepidermin) / Daewoong Pharma
New trial: Efficacy and Safety Evaluation of EASYEF (clinicaltrials.gov) - Apr 19, 2022
P=N/A, N=10, Completed, Sponsor: PT. Daewoong Infion
- | Easyef (nepidermin) / Daewoong Pharma
New trial: Effectiveness of Epidermal Growth Factor-containing Ointment on the Solar Lentigines (clinicaltrials.gov) - Jan 10, 2021
P=N/A, N=40, Completed, Sponsor: Hallym University Kangnam Sacred Heart Hospital
- || Easyef (nepidermin) / Daewoong Pharma
Big day tomorrow. #ADConf19 Ready to Roll! #quickeasyefficient https://t.co/8GG6WVMamq (Twitter) - Dec 14, 2019
- |||| Easyef (nepidermin) / Daewoong Pharma
Trial completion: EGFOM: Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies (clinicaltrials.gov) - Jan 22, 2015
P2, N=138, Completed, Sponsor: Seoul National University Hospital
Heberprot-P75 induced significantly higher wound healing and tissue regeneration activity than Easyef and PBS in the presence or absence of diabetic conditions and cholesterol supplementation. Recruiting --> Completed
- || Easyef (nepidermin) / Daewoong Pharma
Trial primary completion date: EGFOM: Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies (clinicaltrials.gov) - Aug 25, 2014
P2, N=138, Recruiting, Sponsor: Seoul National University Hospital
Recruiting --> Completed Trial primary completion date: Feb 2012 --> Sep 2014